Regulation of liver fibrosis by matrix metalloproteinase/tissue inhibitor of metalloproteinase and research advances in related therapeutic drugs

Qian HUANG; Yan YANG; Rui ZENG; Menglin YAO; Qin SUN

doi:10.3969/j.issn.1001-5256.2022.06.042

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(6): 1420-1425

PDF( 2286 KB)

Regulation of liver fibrosis by matrix metalloproteinase/tissue inhibitor of metalloproteinase and research advances in related therapeutic drugs

DOI: 10.3969/j.issn.1001-5256.2022.06.042

Qian HUANG^1a,
Yan YANG^1b,
Rui ZENG^1b,
Menglin YAO^1b,
Qin SUN^{1b, 2
,
,
,}

1a.
School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China
1b.
School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China
2.
Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, China

Research funding:

Project of Science and Technology Department of Sichuan Province (2021YFH0150);

Luzhou People's Government-Southwest Medical University High-level Talents Introduction Special funding project (2017RC-002);

Southwest Medical University-Southwest Medical University Affiliated Hospital of Traditional Chinese Medicine Joint Project (Southwest Medical University〔2018〕 No.6-51)

More Information

Corresponding author: SUN Qin, zxyjhsq@swmu.edu.cn(ORCID: 0000-0002-6208-150X)
Received Date: 2021-10-11
Accepted Date: 2021-11-16
Published Date: 2022-06-20

Abstract

Abstract

Liver fibrosis is the common consequence of various chronic liver injuries and is mainly characterized by the imbalance between the production and degradation of extracellular matrix, which leads to the accumulation of interstitial collagen and other matrix components. Matrix metalloproteinases (MMPs) and their specific inhibitors, i.e., tissue inhibitors of metalloproteinases (TIMPs), play a crucial role in collagen synthesis and lysis. Through a literature review, this article reviews the experimental studies of liver fibrosis based on MMPs/TIMPs, summarizes the components that may exert an anti-liver fibrosis effect by affecting the expression or activity of MMPs/TIMPs, and attempts to clarify the mechanism of MMPs/TIMPs in regulating collagen homeostasis, so as to provide support for the development of anti-liver fibrosis drugs.
- Liver Cirrhosis,
- Matrix Metalloproteinases,
- Tissue Inhibitor of Metalloproteinases

FullText(HTML)

References(47)

References

[1]	EZHILARASAN D, SOKAL E, NAJIMI M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(3): 192-197. DOI: 10.1016/j.hbpd.2018.04.003.
[2]	SHAN L, LIU Z, CI L, et al. Research progress on the anti-hepatic fibrosis action and mechanism of natural products[J]. Int Immunopharmacol, 2019, 75: 105765. DOI: 10.1016/j.intimp.2019.105765.
[3]	ZHANG J, YANG A, WU Y, et al. Stachydrine ameliorates carbon tetrachloride-induced hepatic fibrosis by inhibiting inflammation, oxidative stress and regulating MMPs/TIMPs system in rats[J]. Biomed Pharmacother, 2018, 97: 1586-1594. DOI: 10.1016/j.biopha.2017.11.117.
[4]	Professional Committee of Liver Diseases, Chinese Society of Integrated Traditional Chinese and Western medicine. Guidelines for the diagnosis and treatment of liver fibrosis with integrated traditional Chinese and Western medicine (2019 edition)[J]. Chin J Integr Med, 2019, 39(11): 1286-1295. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.005. 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 中国中西医结合杂志, 2019, 39(11): 1286-1295. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.005.
[5]	MINKWITZ S, SCHMOCK A, KURTOGLU A, et al. Time-dependent alterations of MMPs, TIMPs and tendon structure in human achilles tendons after acute rupture[J]. Int J Mol Sci, 2017, 18(10): 2199. DOI: 10.3390/ijms18102199.
[6]	LIU X, LIU D, SHEN Y, et al. Matrix metalloproteinases in invertebrates[J]. Protein Pept Lett, 2020, 27(11): 1068-1081. DOI: 10.2174/0929866527666200429110945.
[7]	ROBERT S, GICQUEL T, VICTONI T, et al. Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis[J]. Biosci Rep, 2016, 36(4): e00360. DOI: 10.1042/BSR20160107.
[8]	BREW K, NAGASE H. The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity[J]. Biochim Biophys Acta, 2010, 1803(1): 55-71. DOI: 10.1016/j.bbamcr.2010.01.003.
[9]	KNÄUPER V, BAILEY L, WORLEY JR, et al. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13[J]. FEBS Lett, 2002, 532(1-2): 127-130. DOI: 10.1016/s0014-5793(02)03654-2.
[10]	BOURBOULIA D, STETLER-STEVENSON WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion[J]. Semin Cancer Biol, 2010, 20(3): 161-168. DOI: 10.1016/j.semcancer.2010.05.002.
[11]	ONOZUKA I, KAKINUMA S, KAMIYA A, et al. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice[J]. Biochem Biophys Res Commun, 2011, 406(1): 134-140. DOI: 10.1016/j.bbrc.2011.02.012.
[12]	KOSSAKOWSKA AE, EDWARDS DR, LEE SS, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis[J]. Am J Pathol, 1998, 153(6): 1895-1902. DOI: 10.1016/S0002-9440(10)65703-3.
[13]	ROEB E, PURUCKER E, BREUER B, et al. TIMP expression in toxic and cholestatic liver injury in rat[J]. J Hepatol, 1997, 27(3): 535-544. DOI: 10.1016/s0168-8278(97)80359-5.
[14]	MASHAYEKHI F, SABERI A, MASHAYEKHI S. Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma[J]. Clin Neurol Neurosurg, 2018, 170: 84-87. DOI: 10.1016/j.clineuro.2018.05.001.
[15]	KUNZ P, SÄHR H, LEHNER B, et al. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma[J]. BMC Cancer, 2016, 16: 223. DOI: 10.1186/s12885-016-2266-5.
[16]	XU F, LIU C, ZHOU D, et al. TGFβ/SMAD pathway and its regulation in hepatic fibrosis[J]. J Histochem Cytochem, 2016, 64(3): 157-167. DOI: 10.1369/0022155415627681.
[17]	SUN H, FENG J, TANG L. Function of TREM1 and TREM2 in liver-related diseases[J]. Cells, 2020, 9(12): 2626. DOI: 10.3390/cells9122626.
[18]	HASSAN MH, GHOBARA MM. Antifibrotic effect of meloxicam in rat liver: Role of nuclear factor kappa B, proinflammatory cytokines, and oxidative stress[J]. Naunyn Schmiedebergs Arch Pharmacol, 2016, 389(9): 971-983. DOI: 10.1007/s00210-016-1263-1.
[19]	KARIMI J, MOHAMMADALIPOUR A, SHEIKH N, et al. Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl(4))-induced liver fibrosis in rats[J]. Drug Chem Toxicol, 2020, 43(5): 468-478. DOI: 10.1080/01480545.2018.1504960.
[20]	XIE AZ, LYU C, SHI QL, et al. Research progress on prevention and treatment of liver fibrosis by traditional Chinese medicine[J]. China Med Herald, 2020, 17(17): 34-37. 谢爱泽, 吕超, 石清兰, 等. 中医药防治肝纤维化机制的研究进展[J]. 中国医药导报, 2020, 17(17): 34-37.
[21]	LI J, XU YL, LUO S, et al. Jiawei Yinchen Sini Decoction on MMP1 and TIMPs in carbon tetrachloride-induced hepatic fibrosis mice[J]. Liaoning J Tradit Chin Med, 2016, 43(6): 1315-1317. DOI: 10.13192/j.issn.1000-1719.2016.06.068. 李洁, 徐玉莲, 罗书, 等. 加味茵陈四逆汤对实验性肝纤维化小鼠MMP1和TIMPs表达的影响[J]. 辽宁中医杂志, 2016, 43(6): 1315-1317. DOI: 10.13192/j.issn.1000-1719.2016.06.068.
[22]	LI SM, DAI LJ, FENG L. Effects of Xiaoyao San-containing serum on secretion of MMP-1 and TIMP-1 in human hepatic astrocytes[J]. Lishizhen Med Mater Med Res, 2016, 27(9): 2134-2136. DOI: 10.3969/j.issn.1008-0805.2016.09.029. 李绍民, 代立娟, 冯澜. 逍遥散含药血清对人肝星形细胞分泌MMP-1和TIMP-1的影响[J]. 时珍国医国药, 2016, 27(9): 2134-2136. DOI: 10.3969/j.issn.1008-0805.2016.09.029.
[23]	TIAN XH, WANG Q, SHANG LZ. Role and correlation study of Chaihu Shugan powder on signal pathway of TGF-beta 1/p38MAPK in rat hepatic fibrosis[J]. Chin J Basic Med Tradit Chin Med, 2016, 22(1): 62-65. 田新红, 王琦, 尚立芝. 柴胡疏肝散对肝纤维化大鼠TGF-β1/p38MAPK信号通路的作用及相关性研究[J]. 中国中医基础医学杂志, 2016, 22(1): 62-65.
[24]	AL-OLAYAN EM, EL-KHADRAGY MF, ALAJMI RA, et al. Ceratonia siliqua pod extract ameliorates Schistosoma mansoni-induced liver fibrosis and oxidative stress[J]. BMC Complement Altern Med, 2016, 16(1): 434. DOI: 10.1186/s12906-016-1389-1.
[25]	WEN B, SUN HT, HE SQ, et al. Effects of Biejiajian Pill on Wnt signal pathway molecules β-catenin and GSK-3β and down-stream proteins in hepatic stellate cells[J]. China J Tradit Chin Med Pharma, 2017, 32(9): 3997-4000. 文彬, 孙海涛, 贺松其, 等. 鳖甲煎丸对肝星状细胞中Wnt信号通路信号分子β-catenin、GSK-3β及下游蛋白表达的影响[J]. 中华中医药杂志, 2017, 32(9): 3997-4000.
[26]	HUANG H, KANG Y, HUANG XP, et al. Effect of total flavone from Litchi chinensis Sonn on Smad3, Smad4 and TIMP-1 expression in a rat model of liver fibrosis[J]. World Chin J Dig, 2016, 24(2): 176-186. DOI: 10.11569/wcjd.v24.i2.176. 黄红, 康毅, 黄旭平, 等. 荔枝核总黄酮对大鼠肝纤维化Smad3、Smad4及TIMP-1信号表达的影响[J]. 世界华人消化杂志, 2016, 24(2): 176-186. DOI: 10.11569/wcjd.v24.i2.176.
[27]	ZHAN YY, TIAN LP, WANG JH, et al. Effect of extract of seed melon on the hepatic expressions of cytokines in mice with hepatic fibrosis[J]. J Shihezi Univ Nat Sci, 2016, 34(6): 739-745. DOI: 10.13880/j.cnki.65-1174/n.2016.06.014. 湛园园, 田丽萍, 王金辉, 等. 籽瓜皮提取物对肝纤维化小鼠肝组织细胞因子表达的影响[J]. 石河子大学学报(自然科学版), 2016, 34(6): 739-745. DOI: 10.13880/j.cnki.65-1174/n.2016.06.014.
[28]	AN ZX, HE YL, WANG M. Influence of TGF and MMP in dendrobium nobile polyose on hepatic fibrosis rats[J]. Chin Arch Tradit Chin Med, 2017, 35(3): 530-533. DOI: 10.13193/j.issn.1673-7717.2017.03.004. 安祯祥, 何远利, 王敏. 金钗石斛多糖对肝纤维化大鼠转化生长因子及基质金属蛋白酶的影响[J]. 中华中医药学刊, 2017, 35(3): 530-533. DOI: 10.13193/j.issn.1673-7717.2017.03.004.
[29]	XIONG S, GAO JR, HU ZL. Effect of Carapax Trionycis in inhibiting activation of rat hepatic stellate cell induced by TGF-β[J]. Chin J Exp Tradit Med Formulae, 2017, 23(19): 155-159. DOI: 10.13422/j.cnki.syfjx.2017190155. 熊莎, 高建蓉, 胡祖良. 鳖甲提取物对抑制TGF-β诱导的大鼠肝星状细胞活化的影响[J]. 中国实验方剂学杂志, 2017, 23(19): 155-159. DOI: 10.13422/j.cnki.syfjx.2017190155.
[30]	ZHENG YF, ZHANG YJ, GUO H. Effect of flavonoids from (Maxim) on fibrosing nonalcoholic steatohepatitis in mice[J]. China J Mod Med, 2017, 27(14): 28-32. DOI: 10.3969/j.issn.1005-8982.2017.14.006. 郑玉峰, 张英剑, 郭虹. 溪黄草黄酮对小鼠非酒精性脂肪肝纤维化的影响及其机制探讨[J]. 中国现代医学杂志, 2017, 27(14): 28-32. DOI: 10.3969/j.issn.1005-8982.2017.14.006.
[31]	ZHANG B, TAN YJ, HUANG QJ, et al. Effects of water extract of Mallotus apelta (Lour. ) Muell. -Arg. root on hepatic stellate cells activation and ECM secretion in rats[J]. China J Tradit Chin Med Pharm, 2019, 34(9): 4287-4290. 章波, 檀燕君, 黄秋洁, 等. 白背叶根水提物对大鼠肝星状细胞活化及细胞外基质分泌的影响[J]. 中华中医药杂志, 2019, 34(9): 4287-4290.
[32]	CHEN K, XU JW, ZHOU Q, et al. Effects of all-trans retinioc acid on expressions of COL1α2, MMP-2, TIMP-1, and signaling pathway in TGF-β1-simulated rat hepatic stellate cells[J]. J Xi'an Jiaotong Univ Med Sci, 2019, 36(8): 857-861. DOI: 10.7652/jdyxb201706014. 陈珂, 许君望, 周琦, 等. 全反式维甲酸对TGF-β1刺激的肝星状细胞COL1α2、MMP-2、TIMP-1以及信号通路的影响[J]. 西安交通大学学报(医学版), 2017, 38(6): 857-861. DOI: 10.7652/jdyxb201706014.
[33]	DONG ZC, GAO Q, MAO JN. The regulatory effect of bilobalide on hepatic fibrosis of nonalcoholic steatohepatitis rat via TLR4/TAK1/NF-κB signaling pathway[J]. J Shenyang Pharm Univ, 2019, 36(8): 716-722. DOI: 10.14066/j.cnki.cn21-1349/r.2019.08.012. 董志超, 高琦, 毛建娜. 白果内酯通过TLR4/TAK1/NF-κB通路对非酒精性脂肪肝炎大鼠模型肝纤维化的调控作用[J]. 沈阳药科大学学报, 2019, 36(8): 716-722. DOI: 10.14066/j.cnki.cn21-1349/r.2019.08.012.
[34]	GUO L, LI HZ, WEI YJ. Protective effect of ferulic acid on hepatocytes in rat liver fibrosis and its potential mechanism[J]. J Clin Exp Med, 2019, 18(4): 357-361. DOI: 10.3969/j.issn.1671-4695.2019.04.006. 郭玲, 李惠珍, 魏亚君. 阿魏酸对大鼠肝纤维化过程中肝细胞的保护作用及其可能机制[J]. 临床和实验医学杂志, 2019, 18(4): 357-361. DOI: 10.3969/j.issn.1671-4695.2019.04.006.
[35]	TANG AC, WEI YF, LIU XH. Protective effect and mechanism of tadehaginoside on hepatic fibrosis model mice induced by carbon tetrachloride[J]. China Pharm, 2020, 31(2): 190-195. DOI: 10.6039/j.issn.1001-0408.2020.02.12. 唐爱存, 韦燕飞, 刘喜华. 葫芦茶苷对四氯化碳致肝纤维化模型小鼠的保护作用及机制研究[J]. 中国药房, 2020, 31(2): 190-195. DOI: 10.6039/j.issn.1001-0408.2020.02.12.
[36]	ABU-ELSAAD NM, ELKASHEF WF. Modified citrus pectin stops progression of liver fibrosis by inhibiting galectin-3 and inducing apoptosis of stellate cells[J]. Can J Physiol Pharmacol, 2016, 94(5): 554-562. DOI: 10.1139/cjpp-2015-0284.
[37]	BINGÜL İ, BAŞARAN-KÜÇÜKGERGIN C, AYD₁N AF, et al. Betaine treatment decreased oxidative stress, inflammation, and stellate cell activation in rats with alcoholic liver fibrosis[J]. Environ Toxicol Pharmacol, 2016, 45: 170-178. DOI: 10.1016/j.etap.2016.05.033.
[38]	CLICHICI S, OLTEANU D, FILIP A, et al. Beneficial effects of silymarin after the discontinuation of CCl₄-induced liver fibrosis[J]. J Med Food, 2016, 19(8): 789-797. DOI: 10.1089/jmf.2015.0104.
[39]	THIRUPATHI A, SILVEIRA PC, NESI RT, et al. β-Amyrin, a pentacyclic triterpene, exhibits anti-fibrotic, anti-inflammatory, and anti-apoptotic effects on dimethyl nitrosamine-induced hepatic fibrosis in male rats[J]. Hum Exp Toxicol, 2017, 36(2): 113-122. DOI: 10.1177/0960327116638727.
[40]	MORTEZAEE K, MAJIDPOOR J, DANESHI E, et al. Post-treatment of melatonin with CCl(4) better reduces fibrogenic and oxidative changes in liver than melatonin co-treatment[J]. J Cell Biochem, 2018, 119(2): 1716-1725. DOI: 10.1002/jcb.26331.
[41]	LIN LB, QUE RY, LIU JK. Effect of saikosaponin-d on expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in activated HSC-T6 cells: Underlying mechanism[J]. World Chin J Dig, 2016, 24(8): 1159-1165. DOI: 10.11569/wcjd.v24.i8.1159. 林柳兵, 阙任烨, 刘进锴. 柴胡皂苷d对活化的HSC-T6细胞MMP-1、TIMP-1表达的影响及其分子机制[J]. 世界华人消化杂志, 2016, 24(8): 1159-1165. DOI: 10.11569/wcjd.v24.i8.1159.
[42]	QUE R, SHEN Y, REN J, et al. Estrogen receptor-β-dependent effects of saikosaponind on the suppression of oxidative stress-induced rat hepatic stellate cell activation[J]. Int J Mol Med, 2018, 41(3): 1357-1364. DOI: 10.3892/ijmm.2017.3349.
[43]	SADEK KM, SALEH EA, NASR SM. Molecular hepatoprotective effects of lipoic acid against carbon tetrachloride-induced liver fibrosis in rats: Hepatoprotection at molecular level[J]. Hum Exp Toxicol, 2018, 37(2): 142-154. DOI: 10.1177/0960327117693066.
[44]	SALAMA SM, IBRAHIM I, SHAHZAD N, et al. Hepatoprotectivity of Panduratin A against liver damage: In vivo demonstration with a rat model of cirrhosis induced by thioacetamide[J]. APMIS, 2018, 126(9): 710-721. DOI: 10.1111/apm.12878.
[45]	LIU X, HUANG K, NIU Z, et al. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice[J]. Basic Clin Pharmacol Toxicol, 2019, 124(2): 144-153. DOI: 10.1111/bcpt.13122.
[46]	ZHOU X, YU L, ZHOU M, et al. Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect[J]. Nutr Metab (Lond), 2021, 18(1): 64. DOI: 10.1186/s12986-021-00589-6.
[47]	CAI WM. Some problems in anti-fibrotic therapies[J]. J Clin Hepatol, 2011, 27(3): 225-232. DOI: 10.3969/j.issn.1001-5256.2011.03.001. 蔡为民. 抗肝纤维化治疗研究的若干问题[J]. 临床肝胆病杂志, 2011, 27(3): 225-232. DOI: 10.3969/j.issn.1001-5256.2011.03.001.

Relative Articles

[1]	Daqing LIU, Yan HUANG, Jianhe GAN. Value of serum creatinine-to-cystatin C ratio in assessing the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(2): 264-270. doi: 10.12449/JCH240208
[2]	Wenling LUO, Yu ZENG, Xuemei ZHANG, Yunjian SHENG. Influence of metabolism-related factors on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(10): 1985-1991. doi: 10.12449/JCH241010
[3]	Xiaohua LIU, Shujuan YANG, Yushan LIU, Juan LI, Qiao ZHANG, Yamin WANG, Taotao YAN, Yuan YANG, Yingren ZHAO, Yingli HE. Value of peripheral blood lymphocyte count in evaluating the short－term prognosis of patients with acute－on－chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(10): 2383-2389. doi: 10.3969/j.issn.1001-5256.2023.10.016
[4]	Yan WANG, Ying XU, Wei SUN, Li CHEN, Jianhe GAN, Jing GU. Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1774-1779. doi: 10.3969/j.issn.1001-5256.2022.08.011
[5]	Shaoyu DONG, Changyu SUN, Fangfang QIAO, Xiao LIU, Jianying ZHANG. Value of age and D-dimer combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2478-2482. doi: 10.3969/j.issn.1001-5256.2022.11.008
[6]	Tingting DENG, Li LI, Ying GUAN, Xueyan LUO, Kun QIN, Min LIU. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(10): 2346-2351. doi: 10.3969/j.issn.1001-5256.2022.10.028
[7]	Chenrui LIU, Yaping LI, Sen LUO, Dandan FENG, Fengping WU, Song ZHAI, Shuangsuo DANG. Influencing factors for the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 56-62. doi: 10.3969/j.issn.1001-5256.2021.01.012
[8]	Dongqing ZHANG, Ruidan ZHENG, Minghua LIN, Wenjun WU, Shenglong LIN, Xiangmei WANG, Huaxi MA, Qin LI, Hanhui YE, Haibing GAO. Influencing factors for the 90-day prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2021.10.011
[9]	Xinyi GAO, Li CHEN, Jianhe GAN. Value of Model for End-Stage Liver Disease score combined with platelet-to-white blood cell ratio in predicting the prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(5): 1070-1074. doi: 10.3969/j.issn.1001-5256.2021.05.019
[10]	Yang ShuJuan, Tian Zhen, He YingLi, Zhao YingRen, Zhang Jing, Lu: HengYi, Song HongBo. Predisposing factors for acute-on-chronic liver failure and their influence on prognosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 128-131. doi: 10.3969/j.issn.1001-5256.2020.01.028
[11]	Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
[12]	Li Chen, Tan JunYuan, Xu Xiang. Development and prognosis of acute-on-chronic liver failure in patients with acute deterioration of hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1960-1965. doi: 10.3969/j.issn.1001-5256.2020.09.010
[13]	Tong JingJing, Mu XiuYing, Xu Xiang, Chen Jing, Zhai XingRan, Wang Yu, Su HaiBin, Liu XiaoYan, Hu JinHua. Association between blood ammonia and 90-day prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2019.06.024
[14]	Wang JiaXin, Cheng Na, Xiang TianXin, Li ShuYue, Xiao JinPing, Wu XiaoPing. Establishment and evaluation of short-term prognostic model for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2019.06.023
[15]	Wang Wei, Zhao RongRong, Yang XiaoFei, Huang ZhangXing, Lian JianQi, Wang JiuPing, Zhang Ye. Influence of Notch signaling pathway on interleukin-22 secreted by CD4~+T cells in patients with hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1315-1318. doi: 10.3969/j.issn.1001-5256.2016.07.020
[16]	Li Long, Wu ZhangHui, Wei Jia. Research progress in association between interleukin 28B gene polymorphism and hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1916-1920. doi: 10.3969/j.issn.1001-5256.2015.11.040
[17]	Lu Ying. Correlation of serum interleukin-33 with HBV DNA load and ALT level in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1853-1856. doi: 10.3969/j.issn.1001-5256.2015.11.020
[18]	Tan GuoLei, Sun Mei, Wang JianFang, Wu XuPing. Relationship between IL- 28B polymorphisms and susceptibility to hepatitis C among Han population in Jiangsu Province, China[J]. Journal of Clinical Hepatology, 2014, 30(6): 514-517. doi: 10.3969/j.issn.1001-5256.2014.06.009
[19]	Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 28-31.
[20]	Zuo WeiZe, Xu ChunMei, Shen LanChao. Changes in serum level of interleukin-32 and interleukin-6 in patients with chronic hepatitis B virus infection and its clinical significance[J]. Journal of Clinical Hepatology, 2011, 27(4): 408-410+413.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	李炎，孙永岑. 专科护士主导的O2O多学科管理在肝硬化代偿期患者中的应用. 临床护理杂志. 2024(05): 39-43 .
2.	郝志明，窦琴，包晓云. 基于PI3K/Akt信号通路探讨肝康片对四氯化碳致肝纤维化大鼠肝功能的保护机制. 现代消化及介入诊疗. 2020(02): 188-192 .
3.	朱豫萌，朱丹燕，张国强. 中西药合用治疗慢性乙型病毒性肝炎疗效观察. 实用中医药杂志. 2019(09): 1101-1103 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (1428) PDF downloads(148)

Regulation of liver fibrosis by matrix metalloproteinase/tissue inhibitor of metalloproteinase and research advances in related therapeutic drugs

DOI: 10.3969/j.issn.1001-5256.2022.06.042